Imagion Biosystems Limited (IBX.AX)

Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent

Imagion Biosystems Limited (ASX: IBX) recently announced positive results following completion of the IBI10103 phase I clinical trial evaluating the safety and clinical feasibility of MagSense® HER2 Imaging Agent (MSH2IA) as an adjunct to MRI for the assessment of axillary lymph node metastasis in patients diagnosed with HER2+ primary breast cancer. The trial met its endpoint of safety and tolerability, and showed that blinded radiologists may be able to distinguish suspicious lymph nodes that a